Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) and Abpro (NASDAQ:ABP – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.
Insider & Institutional Ownership
7.4% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 35.0% of Emmaus Life Sciences shares are held by insiders. Comparatively, 13.7% of Abpro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for Emmaus Life Sciences and Abpro, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Emmaus Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Abpro | 1 | 1 | 0 | 0 | 1.50 |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Emmaus Life Sciences | $12.45 million | 0.07 | -$7.49 million | ($0.13) | -0.10 |
| Abpro | N/A | N/A | -$7.23 million | ($4.23) | -0.12 |
Abpro has lower revenue, but higher earnings than Emmaus Life Sciences. Abpro is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Emmaus Life Sciences and Abpro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Emmaus Life Sciences | -70.64% | N/A | -40.35% |
| Abpro | N/A | N/A | -344.76% |
Summary
Emmaus Life Sciences beats Abpro on 5 of the 9 factors compared between the two stocks.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
About Abpro
Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
